Proactiveinvestors recommends
Additional Information
Market: NYSE AMEX
Sector: Pharmaceuticals
EPIC: INO
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Inovio Pharmaceuticals
www.inovio.com

Inovio Pharmaceuticals, Inc. is focused on the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent or treat cancers and chronic infectious diseases. This next generation of immunotherapies could potentially protect millions of people from debilitation or death from diseases without adequate treatments.

DNA vaccines have great potential, but two broad challenges must be overcome to achieve development success. First, scientists must further refine immune system targets in order to design DNA vaccines able to induce clinically relevant immune responses. Second, they must improve DNA delivery capabilities to overcome safety and efficacy limitations common to most existing delivery technologies. Inovio's intellectual property, comprised of the knowledge and expertise of its people, its vaccine design and development processes as well as DNA delivery devices, and its patents, positions the company to potentially overcome these challenges and achieve new clinical breakthroughs.

Full Inovio Pharmaceuticals profile here
Pdf

Inovio Pharmaceuticals to present at Annual Bio conference in New York

6th Feb 2012, 3:34 pm by Brad Lemaire
Inovio Pharmaceuticals to present at Annual Bio conference in New York

Vaccine developer Inovio Pharmaceuticals (NYSE:INO) said early Monday its president and chief executive J. Joseph Kim will give an overview of the company at an investor conference, in New York.

The Blue Bell, Pennsylvania-based company will present at the 14th Annual Bio CEO and Investor Conference, which is slated to take place on February 13 at the Waldorf Astoria Hotel between the hours of 11-11:30 a.m.

A live and archived webcast of the presentation can be accessed on Inovio’s website at http://www.inovio.com/.

Inovio Pharmaceuticals, formerly Inovio Biomedical Corp, is developing DNA-based vaccines, to treat and prevent cancers and infectious diseases.

Its SynCon vaccines are designed to provide broad cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza.

These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown to generate positive immune responses, along with a favourable safety profile.

Inovio's clinical programs include phase II studies for cervical dysplasia (pre-cancerous lesions), leukemia and the hepatitis C virus, as well as phase I studies for influenza and HIV.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.